ClinicalTrials.gg
CompletedNCT01617681Updated Sep 27, 2017Results posted

Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD

A Phase 3 interventional study of VAL489 and VAL489 matching placebo in Pediatric Hypertension With or Without CKD, sponsored by Novartis Pharmaceuticals. Completed at 27 sites in 9 countries. Open to participants aged 1 Year to 5 Years. Per ClinicalTrials.gov, last updated 2017-09-27.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
1 Year to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
83rd of 139
127 · median 198
Started
2012
with 4 others
Phase 3
53 of 140
none open now
Registered
120th of 140
by date
Lead sponsor
19 of 140
Novartis Pharmaceuticals

Among the 140 studies testing valsartan in Hypertension, this one is the 83rd largest by enrollment of the 139 interventional ones that give a count, is one of 5 that started in 2012, is one of 53 in phase 3, and was the 120th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 1 Year to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

To assess efficacy, safety and tolerability of valsartan when comparing two doses of valsartan in reducing and controlling blood pressure in children with hypertension with or without CKD.

03

Conditions studied

  • Pediatric Hypertension With or Without CKD

Browse trials for

Keywords

  • Hypertension; CKD; Pediatric
04

Who can participate

Ages eligible
1 Year to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Patients eligible for inclusion in this study have to fulfill all of the following criteria:

Have the ability to provide written ; Have at baseline , a documented diagnosis of hypertension (as defined in the National High Blood Pressure Education Program 2004); MSBP (mean of 3 measurements) must be ≥95th percentile, and ≤25% above the 95th percentile, for age, gender and height, at baseline; CKD patients must be defined as any of the following criteria: Kidney damage for ≥3 months, as defined by structural or functional abnormalities of the kidney, with or without decreased , manifested by one or more of the following features: Abnormalities in the composition of urine, Abnormalities in imaging tests, Abnormalities on kidney , Estimated eGFR \<60 mL/min/1.73m2 for ≥3 months, with or without the other signs of kidney damage described above; Able to swallow the valsartan solution; Body weight must be ≥8 kg and ≤40 kg at baseline; Must be able to safely washout from other antihypertensive therapy (if applicable) Exclusion criteria /SGOT or ALT/SGPT >3 times the upper limit of the reference range; Estimated Glomerular Filtration Rate [eGFR] \<30 mL/min/1.73m² (calculated using Modified Schwartz Formula); Serum potassium >5.3 mmol/L; Uncontrolled diabetes mellitus, as defined by the investigator; Unilateral, bilateral and graft renal artery stenosis; Current diagnosis of heart failure ( Class II-IV); Patients taking any of the following concomitant medications following screening: RAAS blockers other than study drug, Lithium, Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels; Non-steroidal anti-inflammatory drugs (NSAIDS), including selective COX-2 inhibitors, acetylsalicylic acid >3g/day, and non-selective NSAIDs (paracetamol/acetaminophen is permitted); Antidepressant drugs in the class of MAO inhibitors (e.g. phenelzine); Chronic use of stimulant therapy for ADD/ADHD; patients who have coarctation of the aorta with a gradient of ≥30 mmHg; Previous solid organ transplantation except renal transplantation. Renal transplant must have occurred at least 1 year prior to enrollment; Patient must be on stable doses of therapy and deemed clinically stable by the investigator; Patients known to be positive for the (HIV) Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    Valsartan 0.25 mg/kg

    Valsartan oral solution 0.25mg/kg once daily + matching placebo of valsartan oral solution 4 mg/kg once daily for 6 weeks (period 1)

    Drug: VAL489 · Drug: VAL489 matching placebo

  • Experimental
    Valsartan 4 mg/kg

    Valsartan oral solution 4 mg/kg once daily + matching placebo of valsartan oral solution 0.25 mg/kg once daily for 6 weeks (period 1)

    Drug: VAL489 · Drug: VAL489 matching placebo

  • Experimental
    Valsartan 1 mg/kg

    Open-label (Period 2) valsartan will be optionally titrated from 1 mg/kg to 2 mg/kg. Valsartan will continue to be optionally up titrated in 1 mg/kg increments every 4 weeks until maximum dose of 4 mg/kg is achieved. Duration 20 weeks.

    Drug: VAL489

Interventions

  • DrugVAL489

    Valsartan 3mg/kg oral solution

    Also known as: Diovan

  • DrugVAL489 matching placebo

    Valsartan 3 mg/kg oral solution

    Also known as: Diovan

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Systolic Blood Pressure (MSBP) at Week 6 Endpoint

    Patient's blood pressure will be measured in the same position at every visit Systolic and diastolic blood pressures will be measured three times at 2-3 minute intervals. The arithmetic mean of these three blood pressure measurements will be used as the mean office blood pressure (MSBP and MDBP) at Baseline and Week 6 endpoint in Period 1 Double Blind Phase

    Time frame: Baseline, week 6

Secondary outcomes

  1. Change From Baseline in Mean Diastolic Blood Pressure (MDBP) at Week 6

    Patient's blood pressure will be measured in the same position at every visit Systolic and diastolic blood pressures will be measured three times at 2-3 minute intervals. The arithmetic mean of these three blood pressure measurements will be used as the mean office blood pressure (MSBP and MDBP) Baseline and Week 6 endpoint in Period 1 Double Blind Phase

    Time frame: Baseline, Week 6

  2. Patients Achieving <90th Percentile for Age, Gender and Height at Week 6 Endpoint in Both MSBP and MDBP

    Patient's blood pressure will be measured in the same position at every visit Systolic and diastolic blood pressures will be measured three times at 2-3 minute intervals. The arithmetic mean of these three blood pressure measurements will be used as the mean office blood pressure (MSBP and MDBP) Week 6

    Time frame: Week 6

  3. CKD Patients Achieving Urine Albumin Creatinine Ratio Percentage Reduction (UACR) >=25% at Week 6

    UACR response is defined as percentage change from baseline in UACR≤ 25%. UACR \[mg/mmol\] = urine albumin \[mg/L\] / urine creatinine \[mmol/L\] UACR was collected for CKD patients only. The UACR value at a given visit for a patient was to be derived by the median of the three lab values collected for that visit Week 6.

    Time frame: Week 6 weeks

07

Results

Posted Sep 27, 2017

Participant flow

Overall, 156 patients were screened, of which 127 patients were enrolled in the double blind period 1 of the study. A total of 120 patients (94.5%) completed Period 1 and entered Open Label Period 2.

Period 1 Double Blind
Participant flow — Period 1 Double Blind
MilestoneCKD Patients Valsartan 0.25 mg/kgCKD Patients Valsartan 4 mg/kgNon-CKD Patients Valsartan 0.25 mg/kgNon-CKD Patients Valsartan 4 mg/kgValsartan 1 mg/kg (Period 2)
Started323133310
Full analysis set (fas)313133310
Completed293032290
Not completed31120
Withdrew: Adverse event20020
Withdrew: Withdrawal by subject11100
Period 2 Open Label
Participant flow — Period 2 Open Label
MilestoneCKD Patients Valsartan 0.25 mg/kgCKD Patients Valsartan 4 mg/kgNon-CKD Patients Valsartan 0.25 mg/kgNon-CKD Patients Valsartan 4 mg/kgValsartan 1 mg/kg (Period 2)
Started0000120
Completed0000114
Not completed00006
Withdrew: Adverse event00003
Withdrew: Withdrawal by subject00003

Outcome measures

PrimaryChange From Baseline in Mean Systolic Blood Pressure (MSBP) at Week 6 Endpoint

Patient's blood pressure will be measured in the same position at every visit Systolic and diastolic blood pressures will be measured three times at 2-3 minute intervals. The arithmetic mean of these three blood pressure measurements will be used as the mean office blood pressure (MSBP and MDBP) at Baseline and Week 6 endpoint in Period 1 Double Blind Phase

Time frame:
Baseline, week 6
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Systolic Blood Pressure (MSBP) at Week 6 Endpoint
mmHgCKD Patients Valsartan 0.25 mg/kgCKD Patients Valsartan 4 mg/kgNon-CKD Patients Valsartan 0.25 mg/kgNon-CKD Patients Valsartan 4 mg/kg
Change From Baseline in Mean Systolic Blood Pressure (MSBP) at Week 6 Endpoint-1.2 ± 2.05-9.2 ± 2.05-6.9 ± 1.44-7.8 ± 1.48
Statistical analysis
  • CKD Patients Valsartan 0.25 mg/kg vs CKD Patients Valsartan 4 mg/kg · ANCOVA · p = 0.0096 · Mean difference (net): -7.9 · 95% CI -13.86 to -2.01
  • Non-CKD Patients Valsartan 0.25 mg/kg vs Non-CKD Patients Valsartan 4 mg/kg · ANCOVA · p = 0.6531 · Mean difference (net): -0.9 · 95% CI -5.07 to 3.20
SecondaryChange From Baseline in Mean Diastolic Blood Pressure (MDBP) at Week 6

Patient's blood pressure will be measured in the same position at every visit Systolic and diastolic blood pressures will be measured three times at 2-3 minute intervals. The arithmetic mean of these three blood pressure measurements will be used as the mean office blood pressure (MSBP and MDBP) Baseline and Week 6 endpoint in Period 1 Double Blind Phase

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Diastolic Blood Pressure (MDBP) at Week 6
mmHgCKD Patients Valsartan 0.25 mg/kgCKD Patients Valsartan 4 mg/kgNon-CKD Patients Valsartan 0.25 mg/kgNon-CKD Patients Valsartan 4 mg/kg
Change From Baseline in Mean Diastolic Blood Pressure (MDBP) at Week 61.3 ± 1.79-6.5 ± 1.79-1.9 ± 1.26-7.2 ± 1.30
Statistical analysis
  • CKD Patients Valsartan 0.25 mg/kg vs CKD Patients Valsartan 4 mg/kg · ANCOVA · p = 0.0030 · Mean difference (net): -7.9 · 95% CI -12.94 to -2.78
  • Non-CKD Patients Valsartan 0.25 mg/kg vs Non-CKD Patients Valsartan 4 mg/kg · ANCOVA · p = 0.0042 · Mean difference (net): -5.4 · 95% CI -8.98 to -1.77
SecondaryPatients Achieving <90th Percentile for Age, Gender and Height at Week 6 Endpoint in Both MSBP and MDBP

Patient's blood pressure will be measured in the same position at every visit Systolic and diastolic blood pressures will be measured three times at 2-3 minute intervals. The arithmetic mean of these three blood pressure measurements will be used as the mean office blood pressure (MSBP and MDBP) Week 6

Time frame:
Week 6
Reported as:
Number · participants
Patients Achieving <90th Percentile for Age, Gender and Height at Week 6 Endpoint in Both MSBP and MDBP
participantsCKD Patients Valsartan 0.25 mg/kgCKD Patients Valsartan 4 mg/kgNon-CKD Patients Valsartan 0.25 mg/kgNon-CKD Patients Valsartan 4 mg/kg
Patients Achieving <90th Percentile for Age, Gender and Height at Week 6 Endpoint in Both MSBP and MDBP6978
Statistical analysis
  • CKD Patients Valsartan 0.25 mg/kg vs CKD Patients Valsartan 4 mg/kg · ANCOVA · p = 0.411 · Odds ratio (or): 1.68 · 95% CI 0.49 to 5.8
  • Non-CKD Patients Valsartan 0.25 mg/kg vs Non-CKD Patients Valsartan 4 mg/kg · ANCOVA · p = 0.5443 · Odds ratio (or): 1.45 · 95% CI 0.44 to 4.79
SecondaryCKD Patients Achieving Urine Albumin Creatinine Ratio Percentage Reduction (UACR) >=25% at Week 6

UACR response is defined as percentage change from baseline in UACR≤ 25%. UACR \[mg/mmol\] = urine albumin \[mg/L\] / urine creatinine \[mmol/L\] UACR was collected for CKD patients only. The UACR value at a given visit for a patient was to be derived by the median of the three lab values collected for that visit Week 6.

Time frame:
Week 6 weeks
Reported as:
Number · participants
CKD Patients Achieving Urine Albumin Creatinine Ratio Percentage Reduction (UACR) >=25% at Week 6
participantsCKD Patients Valsartan 0.25 mg/kgCKD Patients Valsartan 4 mg/kg
CKD Patients Achieving Urine Albumin Creatinine Ratio Percentage Reduction (UACR) >=25% at Week 6129
Statistical analysis
  • CKD Patients Valsartan 0.25 mg/kg vs CKD Patients Valsartan 4 mg/kg · ANCOVA · p = 0.2624 · Odds ratio (or): 0.517 · 95% CI 0.16 to 1.64

Adverse events

Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valsartan 0.25 mg/kg0/64 (0%)2/64 (3.1%)19/64 (29.7%)
Valsartan 4.0 mg/kg0/62 (0%)2/62 (3.2%)13/62 (21%)
All Open Label Patients0/120 (0%)6/120 (5%)62/120 (51.7%)
Most frequent serious events
Most frequent serious events
EventValsartan 0.25 mg/kgValsartan 4.0 mg/kgAll Open Label Patients
GastroenteritisInfections and infestations0/640/622/120
GastritisGastrointestinal disorders0/641/620/120
BronchitisInfections and infestations1/641/620/120
AggressionPsychiatric disorders1/640/620/120
Oedema peripheralGeneral disorders0/640/621/120
MastoiditisInfections and infestations0/640/621/120
PharyngitisInfections and infestations0/640/621/120
Toxicity to various agentsInjury, poisoning and procedural complications0/640/621/120
Nephrotic syndromeRenal and urinary disorders0/640/621/120
Most frequent other events
Most frequent other events
EventValsartan 0.25 mg/kgValsartan 4.0 mg/kgAll Open Label Patients
PyrexiaGeneral disorders2/643/6220/120
CoughRespiratory, thoracic and mediastinal disorders5/641/6211/120
DiarrhoeaGastrointestinal disorders4/642/6210/120
Upper respiratory tract infectionInfections and infestations1/640/6210/120
VomitingGastrointestinal disorders3/641/629/120
NasopharyngitisInfections and infestations3/642/629/120
TonsillitisInfections and infestations0/642/628/120
Respiratory tract infectionInfections and infestations4/643/626/120
BronchitisInfections and infestations3/640/627/120
Ear infectionInfections and infestations0/640/627/120

Baseline characteristics

Age, Continuous
Age, Continuous(years)CKD Patients Valsartan 0.25 mg/kgCKD Patients Valsartan 4 mg/kgNon-CKD Patients Valsartan 0.25 mg/kgNon-CKD Patients Valsartan 4 mg/kgTotal
Mean2.99 ± 1.472.72 ± 1.333.7 ± 1.513.62 ± 1.363.26 ± 1.466
Sex: Female, Male
Sex: Female, Male(Participants)CKD Patients Valsartan 0.25 mg/kgCKD Patients Valsartan 4 mg/kgNon-CKD Patients Valsartan 0.25 mg/kgNon-CKD Patients Valsartan 4 mg/kgTotal
Female128141347
Male2023191880
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CKD Patients Valsartan 0.25 mg/kgCKD Patients Valsartan 4 mg/kgNon-CKD Patients Valsartan 0.25 mg/kgNon-CKD Patients Valsartan 4 mg/kgTotal
Hispanic or Latino1216141557
Not Hispanic or Latino2015191670
Unknown or Not Reported00000
08

Study locations

27 sites
  • Novartis Investigative Site
    Antwerpen, 2020, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Curitibia, Parana 80250-060, Brazil
  • Novartis Investigative Site
    Campinas, 13087-567, Brazil
  • Novartis Investigative Site
    Caxias do Sul, 95070-561, Brazil
  • Novartis Investigative Site
    Porto Alegre, 90610-000, Brazil
  • Novartis Investigative Site
    Montpellier, 34059, France
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Marburg, 35039, Germany
  • Novartis Investigative Site
    Guatemala City, 01010, Guatemala
  • Novartis Investigative Site
    Guatemala, 01001, Guatemala
  • Novartis Investigative Site
    Guatemala, 1010, Guatemala
  • Novartis Investigative Site
    Budapest, H 1096, Hungary
  • Novartis Investigative Site
    Budapest, H-1083, Hungary
  • Novartis Investigative Site
    Szeged, 6725, Hungary
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    San Donato Milanese, MI 20097, Italy
  • Novartis Investigative Site
    Palermo, 90134, Italy
  • Novartis Investigative Site
    Vinius, 08406, Lithuania
  • Novartis Investigative Site
    Bialystok, 15-274, Poland
  • Novartis Investigative Site
    Gdansk, 80-952, Poland
  • Novartis Investigative Site
    Krakow, 30-663, Poland
  • Novartis Investigative Site
    Lodz, 93-338, Poland
  • Novartis Investigative Site
    Lublin, 20-093, Poland
  • Novartis Investigative Site
    Poznan, 61-825, Poland
  • Novartis Investigative Site
    Szczecin, 71-252, Poland
  • Novartis Investigative Site
    Warszawa, 04-154, Poland
09

References and documents

Publications

  • Jankauskiene A, Drozdz D, Wasilewska A, de Paula-Bernardes R, Glazer R, Valentin M, Tan M, Chiang Y, Bapatla K. Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: a randomized, double-blind study followed by open-label phase. Curr Med Res Opin. 2021 Dec;37(12):2113-2122. doi: 10.1080/03007995.2021.1982681. Epub 2021 Oct 9. PubMed 34543161 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2012 to primary completion in Jan 2017, 50 months.

Results were first posted in Sep 2017, 8 months after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 50 months is above that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2012
First posted
Jun 12, 2012
StartActual
Nov 8, 2012
Primary completionActual
Jan 24, 2017
CompletionActual
Jan 24, 2017
Results first posted
Sep 27, 2017
Last update
Sep 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01617681
Responsible party
Sponsor
First posted
Jun 12, 2012
Start date
Nov 8, 2012
Primary completion
Jan 24, 2017
Completion
Jan 24, 2017
Results posted
Sep 27, 2017
Last update
Sep 27, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion